Catalyst Pharmaceuticals Inc (CPRX)
15.12
-0.22
(-1.47%)
USD |
NASDAQ |
Apr 19, 16:00
15.13
+0.02
(+0.10%)
After-Hours: 16:36
Catalyst Pharmaceuticals Enterprise Value: 1.670B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 1.670B |
| April 17, 2024 | 1.748B |
| April 16, 2024 | 1.694B |
| April 15, 2024 | 1.676B |
| April 12, 2024 | 1.656B |
| April 11, 2024 | 1.726B |
| April 10, 2024 | 1.734B |
| April 09, 2024 | 1.723B |
| April 08, 2024 | 1.690B |
| April 05, 2024 | 1.650B |
| April 04, 2024 | 1.644B |
| April 03, 2024 | 1.688B |
| April 02, 2024 | 1.661B |
| April 01, 2024 | 1.718B |
| March 28, 2024 | 1.741B |
| March 27, 2024 | 1.780B |
| March 26, 2024 | 1.719B |
| March 25, 2024 | 1.732B |
| March 22, 2024 | 1.716B |
| March 21, 2024 | 1.821B |
| March 20, 2024 | 1.855B |
| March 19, 2024 | 1.794B |
| March 18, 2024 | 1.758B |
| March 15, 2024 | 1.756B |
| March 14, 2024 | 1.771B |
| Date | Value |
|---|---|
| March 13, 2024 | 1.821B |
| March 12, 2024 | 1.772B |
| March 11, 2024 | 1.760B |
| March 08, 2024 | 1.778B |
| March 07, 2024 | 1.824B |
| March 06, 2024 | 1.732B |
| March 05, 2024 | 1.780B |
| March 04, 2024 | 1.830B |
| March 01, 2024 | 1.867B |
| February 29, 2024 | 1.752B |
| February 28, 2024 | 1.578B |
| February 27, 2024 | 1.554B |
| February 26, 2024 | 1.534B |
| February 23, 2024 | 1.534B |
| February 22, 2024 | 1.517B |
| February 21, 2024 | 1.495B |
| February 20, 2024 | 1.504B |
| February 16, 2024 | 1.529B |
| February 15, 2024 | 1.516B |
| February 14, 2024 | 1.467B |
| February 13, 2024 | 1.432B |
| February 12, 2024 | 1.486B |
| February 09, 2024 | 1.486B |
| February 08, 2024 | 1.434B |
| February 07, 2024 | 1.432B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
175.38M
Minimum
Mar 16 2020
1.917B
Maximum
Jan 13 2023
738.65M
Average
485.32M
Median
Enterprise Value Benchmarks
| Pfizer Inc | 201.80B |
| Sarepta Therapeutics Inc | 10.50B |
| PTC Therapeutics Inc | 3.114B |
| Corcept Therapeutics Inc | 1.980B |
| Cytokinetics Inc | 6.904B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 34.84M |
| Revenue (Quarterly) | 110.57M |
| Total Expenses (Quarterly) | 68.88M |
| EPS Diluted (Quarterly) | 0.31 |
| Gross Profit Margin (Quarterly) | 85.70% |
| Profit Margin (Quarterly) | 31.51% |
| Earnings Yield | 4.04% |
| Operating Earnings Yield | 5.13% |
| Normalized Earnings Yield | 4.036 |